HIV variability and perspectives for a vaccine

Vaccine. 1993;11(5):542-4. doi: 10.1016/0264-410x(93)90227-o.

Abstract

An overview of efforts to induce neutralizing antibodies in order to develop an effective vaccine against AIDS is presented. The principal Neutralizing Determinant (PND) on the HIV-1 envelope is described. PND variability and the induction of neutralizing antibodies by synthetic peptides representing PND are discussed. The use of a cocktail of different peptides representing the PND sequences of the majority of HIV-1 isolates, as well as the construction of hybrid immunogens containing PND of several viral isolates, could overcome the problems related to PND variability. A different approach based on the possibility of inducing a type of intracellular immunity is also discussed: a cellular clone (F12) obtained in our laboratory from Hut-78 cells infected with supernatant of cultured lymphocytes from an HIV-infected patient, does not release viral particles despite the presence of a full-length HIV-1 provirus. Moreover, F12 cells are fully resistant against superinfection with any HIV-1 or HIV-2 isolates. We are now attempting to reproduce the homologous viral interference by transferring the F12/HIV genome of the clone into HIV-susceptible cells in order to render these cells resistant to HIV infection.

Publication types

  • Review

MeSH terms

  • AIDS Vaccines*
  • Amino Acid Sequence
  • Animals
  • Cell Line
  • HIV Antibodies / biosynthesis*
  • HIV Envelope Protein gp120 / immunology*
  • HIV-1 / immunology*
  • HIV-1 / physiology
  • HIV-2 / immunology
  • HIV-2 / physiology
  • Molecular Sequence Data
  • Neutralization Tests
  • Pan troglodytes
  • Peptide Fragments / immunology*
  • Proviruses / physiology
  • Viral Interference

Substances

  • AIDS Vaccines
  • HIV Antibodies
  • HIV Envelope Protein gp120
  • HIV envelope protein gp120 (305-321)
  • Peptide Fragments